To assess whether LIF signaling is a therapeutic pathway for the treatment of breast cancer by targeting breast CSCs, a special LIF receptor blockade antibody was utilized to inhibit this pathway in breast cancer cells. This evidence concerns the gene LIFR and breast cancer.